Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
Recorded Q4'24 consolidated revenue of KRW 1.26 trillionRecorded FY'24 consolidated revenue of KRW 4.55 trillionPoised for further growth with expanded capacity and new service offerings